SEC Filing Summary: Trovagene, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on March 5, 2020. The registrant is a Delaware corporation with principal executive offices in San Diego, CA, and its common stock trades on the Nasdaq Capital Market under the symbol TROV.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance events and does not contain financial statements or performance metrics.
Material Changes
The primary event reported is the nomination of three new board members proposed for election at the Company's annual meeting of shareholders scheduled for April 16, 2020. The nominees are:
- James Armitage, MD
- Lâle White
- Gary Pace, PhD
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document focuses solely on the board nomination announcement.
Key Facts for Investor Verification
- Verify the company name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Confirm the election date for the new board members is April 16, 2020.
- Review the attached press release (Exhibit 99.1) for detailed biographies of the nominees.
- Note that no financial data is included in this specific filing.